Device Trial Radar · NCT04502212
Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DM
Last checked: Nov 20, 2026Latest source record: Jun 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jul 30, 2020
Primary completion
May 24, 2021
Study completion May 24, 2021
Sponsor
- Lead sponsor
- General Electric ResearchNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- ProSciento, Inc.
- First posted
- Aug 6, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is being done to evaluate the effect of hepatic ultrasound insonification on whole-body insulin sensitivity and evaluate the safety and tolerability of hepatic ultrasound insonification in subjects with Type 2 Diabetes Mellitus (T2DM). "Insonify/insonification" is defined as applying to an area or an object carefully-controlled sound waves, typically as in ultrasound imaging. GE Research is sponsoring this research study. The purpose of this research study is to: * Evaluate the effect of liver ultrasound waves on changes from baseline in whole-body insulin sensitivity * Test the safety and tolerability of liver ultrasound waves in subjects with Type 2 Diabetes Mellitus * Evaluate the effect of liver ultrasound waves on change from baseline in glucose tolerance and insulin secretion * Evaluate the effect of liver ultrasound waves on glucose metabolism Insulin sensitivity refers to how sensitive the body's cells are in response to insulin. Glucose tolerance refers to the body's ability to handle (tolerate) glucose. Insulin secretion is a process in which the body releases insulin in response to glucose levels in the blood becoming elevated. The study device used in this study is cleared for use by the United States Food and Drug Administration (FDA) for ultrasound diagnostic exams, however it has not been tested or approved specifically for modulation of metabolism in people with diabetes. The use of the study device in this study is investigational and is considered a Non-Significant Risk (NSR).
Conditions
- Type 2 Diabetes
Interventions
Hepatic Ultrasound InsonificationDevice
Hepatic ultrasound insonification will be performed after an overnight fast (no food or drinks except for water for at least 10 hours) at approximately the same time on each day for three days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Glucose Disposal Rate: Insulin Ratio During Steady State (M/I)Time frame: Day 2 (Baseline) to Day 17
- Change From Baseline in Endogenous Glucose Production (EGP)Time frame: Day 2 (Baseline) to Day 17
- Change From Baseline in Insulin-Mediated EGP Suppression During the Clamp Timepoint With Low Rate Insulin Infusion (Step 1)Time frame: Day 2 (Baseline) to Day 17
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ProSciento
Chula Vista, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.